Cancer Institute, The Fourth Hospital of Hebei Medical University/The Tumor Hospital of Hebei Province, Shijiazhuang, China.
Biomol Biomed. 2023 Sep 4;23(5):883-893. doi: 10.17305/bb.2023.8804.
Osteosarcoma, a rare malignant tumor, has a poor prognosis. This study aimed to find the best prognostic model for osteosarcoma. There were 2912 patients included from the SEER database and 225 patients from Hebei Province. Patients from the SEER database (2008-2015) were included in the development dataset. Patients from the SEER database (2004-2007) and Hebei Province cohort were included in the external test datasets. The Cox model and three tree-based machine learning algorithms (survival tree [ST], random survival forest [RSF] and gradient boosting machine [GBM]) were used to develop the prognostic models by 10-fold cross-validation with 200 iterations. Additionally, performance of models in the multivariable group was compared with the TNM group. The 3-year and 5-year cancer specific survival (CSS) were 72.71% and 65.92% in the development dataset, respectively. The predictive ability in the multivariable group was superior to that in the TNM group. The calibration curves and consistency in the multivariable group were superior to those in the TNM group. The Cox and RSF models performed better than the ST and GBM models. A nomogram was constructed to predict the 3-year and 5-year CSS of osteosarcoma patients. The RSF model can be used as a nonparametric alternative to the Cox model. The constructed nomogram based on the Cox model can provide reference for clinicians to formulate specific therapeutic decisions both in America and China.
骨肉瘤是一种罕见的恶性肿瘤,预后较差。本研究旨在寻找骨肉瘤最佳预后模型。本研究纳入了 SEER 数据库中的 2912 例患者和河北省的 225 例患者。SEER 数据库(2008-2015 年)中的患者纳入开发数据集。SEER 数据库(2004-2007 年)和河北省队列中的患者纳入外部测试数据集。采用 Cox 模型和三种基于树的机器学习算法(生存树[ST]、随机生存森林[RSF]和梯度提升机[GBM]),通过 200 次迭代的 10 折交叉验证来开发预后模型。此外,还比较了多变量组与 TNM 组的模型性能。在开发数据集中,患者的 3 年和 5 年癌症特异性生存率(CSS)分别为 72.71%和 65.92%。多变量组的预测能力优于 TNM 组。多变量组的校准曲线和一致性优于 TNM 组。Cox 模型和 RSF 模型的性能优于 ST 和 GBM 模型。构建了一个列线图来预测骨肉瘤患者的 3 年和 5 年 CSS。RSF 模型可以作为 Cox 模型的非参数替代模型。基于 Cox 模型构建的列线图可以为中美两国的临床医生制定特定的治疗决策提供参考。